Jade Biosciences, Inc. · NASDAQ:JBIO
Jade Biosciences — Technical Presentation (June 2026)
22 slides from Jade Biosciences's technical presentation, Jun 1, 2026
Slide 1: JADE101 Phase 1 Interim Data Conference Call
June 1, 2026 JADE101 Phase 1 Interim Data Conference Call NAS DAQ: JBI O
Slide 2: Disclaimers
Disclaimers FO RW AR D L O O K IN G S TA T EM E N TS Certain statements contained in or made orally during this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe h
Slide 3: JADE101 Phase 1 study met or exceeded objectives
JADE101 Phase 1 study met or exceeded objectives J A D E1 0 1 Clinical data support potential for every-12-week subcutaneous dosing with best-in-class, disease- modifying potential ENDPOINT JAD E101 OBJECT IVE JAD E101 DAT A Dosing ▪ Single SC maintenance dose Q8W Potential for single SC maintenance
Slide 4: Potentially best-in-class properties of JADE101
Potentially best-in-class properties of JADE101 J A D E1 0 1 Fully-human, ultra-high binding affinity, and extended half-life Novel epitope discovered through de novo campaign to Ultra-high (fM) APRIL binding achieve first fully-human, affinity potentially best-in-class anti- ▪ Binds APRIL to neutra
Slide 5: IgAN is a $20B+ potential market in the U.S. alone
IgAN is a $20B+ potential market in the U.S. alone J A D E1 0 1 ~169K+ IgAN patients in the U.S., with 60-75% ~1M+ global patients, significant ex-U.S. requiring treatment per international guidelines market potential Require Treatment No Additional Treatment Required U.S. E.U. Japan China 0 50,000
Slide 6: A need for effective and convenient therapies for lifelong treatment
A need for effective and convenient therapies for J A D E1 0 1 lifelong treatment High lifetime risk of end-stage kidney disease IgAN is a progressive autoimmune kidney disease requiring lifelong treatment, with significant need for well-tolerated, disease- modifying therapies that offer convenient
Slide 7: Updated KDIGO guidelines position the anti-APRIL class as the foundational therapy in IgAN
Updated KDIGO guidelines position the anti-APRIL class as J A D E1 0 1 the foundational therapy in IgAN KDIGO updates: IgAN patients at risk of progressive kidney ▪ Expected to increase IgAN function loss diagnosis ▪ Expand at-risk patient In all patients these population requiring Drivers of Manage
Slide 8: IgA responses are consistent between HVs and IgAN patients and predictive of clinical activity
IgA responses are consistent between HVs and IgAN J A D E1 0 1 patients and predictive of clinical activity IgA reduction in HVs is highly correlated with IgA …and early IgA reduction further correlates with reduction in IgAN patients at multiple time points… W36 UPCR reduction, in IgAN patients M E
Slide 9: JADE101 Interim Phase 1 Data
JADE101 Interim Phase 1 Data 9
Slide 10: JADE101 Phase 1 study ongoing
JADE101 Phase 1 study ongoing P HAS E 1 D ES I G N Dose levels and length of follow-up to date ▪ Randomized, double-blind, placebo- controlled ▪ Single ascending dose 17 5M G S C: Follow-up: ~8 months N = 6: 2 ▪ Subcutaneous administration (175 mg/mL) P O P U LA TIO N 35 0M G S C: Maintenance dose ▪
Slide 11: Baseline characteristics were typical of healthy volunteers
Baseline characteristics were typical of healthy volunteers P HAS E 1 J A D E1 01 A N D 1 75 M G 3 50 M G 7 00 M G 1 40 0 M G AL L COHOR TS P L A C EB O N 8 8 8 8 32 Age, (yr), 38.0 (7.86) 44.5 (9.87) 28.0 (9.04) 37.6 (13.70) 37.0 (11.51) Mean (SD) Female 2 (25) 6 (75) 3 (38) 5 (63) 16 (50) N (%) Wh
Slide 12: JADE101 demonstrated favorable safety profile and was well tolerated across all evaluated doses
JADE101 demonstrated favorable safety profile and was well P HAS E 1 tolerated across all evaluated doses ▪ No severe AEs or deaths Healthy Volunteer SAD Safety Summary ▪ All TEAEs were mild/moderate in J A D E1 01 A N D AL L severity P L A C EB O 1 75 M G 3 50 M G 7 00 M G 1 40 0 M G COHOR TS ▪ No
Slide 13: JADE101 single dose IgA reductions exceeded those reported with first-generation molecules
JADE101 single dose IgA reductions exceeded those P HAS E 1 reported with first-generation molecules IgA Change from IgA reduction in Healthy Baseline by Dose Volunteers ▪ Prolonged IgA reductions of ~70% 20 S I BE P R E N LI M A B PO VE T A C IC E PT J AD E 1 0 1 following a single dose of JADE101
Slide 14: JADE101 demonstrated compelling in vivo potency to lower IgA
JADE101 demonstrated compelling in vivo potency to lower P HAS E 1 IgA APRIL Binding Affinity and IgA Lowering Potency ▪ Ultra-high APRIL binding affinity predicted JADE101’s enhanced in vivo potency to lower serum IgA in humans 1000 Ataci ▪ JADE101 has shown rapid, deep and sustained IgA depletion
Slide 15: PD modeling supports Q12W maintenance dosing
JADE101 PD modeling supports Q12W maintenance dosing P HAS E 1 Deeper IgA reductions simulated over first-generation anti-APRILs Simulated IgA vs Time – 48 weeks ▪ JADE101 induction dose (700 mg) 0 predicted to rapidly maximize IgA depletion -10 ▪ >70% IgA reductions projected at JADE101 350 mg SC Q
Slide 16: IgA reductions for 12 weeks enabled by dose-dependent PK and fAPRIL suppression
IgA reductions for 12 weeks enabled by dose-dependent PK P HAS E 1 and rapid, complete, and sustained fAPRIL suppression Pharmacokinetics fAPRIL ▪ ~8.7 fold longer half-life than povetacicept; ~2.6 fold longer than sibeprenlimab 100 ▪ JADE101 half-life: 24.2 days 50 J A DE 1 0 1 C O N C . ( μ g / m
Slide 17: Changes in IgG, IgM and IgE were consistent with the selective anti-APRIL MoA
Changes in IgG, IgM and IgE were consistent with the P HAS E 1 selective anti-APRIL MoA IgG IgM IgE ▪ Magnitude of IgG- lowering consistent 10 10 with relatively IgG- 0 0 0 sparing selective- 10 50 10 I g M C FB ( % ) anti-APRIL MoA I g G C FB (% ) I gE CF B ( %) 30 ▪ No cases of IgG 30 30 10 0 ≤ 3
Slide 18: JADE101 Next Steps
JADE101 Next Steps 18
Slide 19: Q12W dosing expected to optimize clinical activity and convenience for patients
Q12W dosing expected to optimize clinical activity and N E X T ST EP S convenience for patients ▪ Plan to evaluate two dosing regimens (Q12W and Q8W) in Phase 2 and Phase 3 ▪ Two dose Phase 3 may enable an accelerated Phase 3 initiation without awaiting Phase 2 data ▪ Supports global regulatory expe
Slide 20: JADE101 Phase 2 IgAN patient trial initiated; interim data anticipated in 2027
JADE101 Phase 2 IgAN patient trial initiated; interim data N E X T ST EP S anticipated in 2027 W E EK 0 D ES I G N Induction Dose 700 mg ▪ Randomized, open-label ▪ Subcutaneous administration P O P U LA TIO N W E EK 4 ▪ Adults with IgAN within 5 yrs Maintenance Dosing 350 mg ▪ Proteinuria ≥0. 5g/g ▪
Slide 21: Advancing potentially best-in-class therapies for autoimmune diseases
Advancing potentially best-in-class therapies for C O M P A N Y O V E R V IE W autoimmune diseases Well-capitalized with $311 million in cash (1); runway expected into 1H 2028 POTE NTIA L P ROG R AM MO A P RE C LINIC AL P HAS E 1 P HAS E 2 P HAS E 3 IND ICA TIONS Candidates designed to maximize clin
Slide 22: Thank you
Thank you JADEBIOSCIENCES.COM INFO@JA DEBIOSCI ENCES.COM NASDAQ: JBIO
Jade Biosciences — Technical Presentation (June 2026) on 6ix